Publications by authors named "Federica Predolini"

Claim this Profile
I
Inhibition of BET Bromodomain Proteins with GS-5829 and GS-626510 in Uterine Serous Carcinoma, a Biologically Aggressive Variant of Endometrial Cancer.
Elena Bonazzoli, Federica Predolini, Emiliano Cocco, Stefania Bellone, Gary Altwerger

Clin Cancer Res· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
7
7-Hydroxymatairesinol improves body weight, fat and sugar metabolism in C57BJ/6 mice on a high-fat diet.
Giorgio Biasiotto, Isabella Zanella, Federica Predolini, Ivonne Archetti, Moris Cadei

Br J Nutr· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine and Ovarian Carcinosarcoma with HER2/Neu Expression.
Gulden Menderes, Elena Bonazzoli, Stefania Bellone, Jonathan Black, Federica Predolini

Clin Cancer Res· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Polymerase ε (POLE) ultra-mutation in uterine tumors correlates with T lymphocyte infiltration and increased resistance to platinum-based chemotherapy in vitro.
Stefania Bellone, Eliana Bignotti, Silvia Lonardi, Francesca Ferrari, Floriana Centritto, Federica Predolini

Gynecol Oncol· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial-mesenchymal transition.
Siming Zhao, Stefania Bellone, Salvatore Lopez, Durga Thakral, Carlton Schwab, Federica Predolini

Proc Natl Acad Sci U S A· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine Serous Carcinoma with HER2/Neu Expression.
Jonathan Black, Gulden Menderes, Stefania Bellone, Carlton L Schwab, Elena Bonazzoli, Federica Predolini

Mol Cancer Ther· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dual CCNE1/PIK3CA targeting is synergistic in CCNE1-amplified/PIK3CA-mutated uterine serous carcinomas in vitro and in vivo.
Emiliano Cocco, Salvatore Lopez, Jonathan Black, Stefania Bellone, Elena Bonazzoli, Federica Predolini

Br J Cancer· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE), is highly active against primary uterine serous papillary carcinoma cell lines in vitro.
Stefania Bellone, Jonathan Black, Diana P English, Carlton L Schwab, Salvatore Lopez, Federica Predolini

Am J Obstet Gynecol· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas.
Jonathan D Black, Salvatore Lopez, Emiliano Cocco, Stefania Bellone, Gary Altwerger, Federica Predolini

Br J Cancer· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dual HER2/PIK3CA Targeting Overcomes Single-Agent Acquired Resistance in HER2-Amplified Uterine Serous Carcinoma Cell Lines In Vitro and In Vivo.
Salvatore Lopez, Emiliano Cocco, Jonathan Black, Stefania Bellone, Elena Bonazzoli, Federica Predolini

Mol Cancer Ther· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neratinib shows efficacy in the treatment of HER2 amplified carcinosarcoma in vitro and in vivo.
Carlton L Schwab, Diana P English, Jonathan Black, Stefania Bellone, Salvatore Lopez, Federica Predolini

Gynecol Oncol· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE®), is highly active against primary uterine and ovarian carcinosarcoma cell lines in vitro.
Francesca Ferrari, Stefania Bellone, Jonathan Black, Carlton L Schwab, Salvatore Lopez, Federica Predolini

J Exp Clin Cancer Res· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas.
Jonathan D Black, Salvatore Lopez, Emiliano Cocco, Stefania Bellone, Gary Altwerger, Federica Predolini

Br J Cancer· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dacomitinib (PF-00299804), a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor, demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro.
Liancheng Zhu, Salvatore Lopez, Stefania Bellone, Jonathan Black, Emiliano Cocco, Federica Predolini

Tumour Biol· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Polymerase ε (POLE) ultra-mutated tumors induce robust tumor-specific CD4+ T cell responses in endometrial cancer patients.
Stefania Bellone, Floriana Centritto, Jonathan Black, Carlton Schwab, Diana English, Federica Predolini

Gynecol Oncol· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis